

VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001073

Report Form

Serious Adverse Event Report Form

Please send this report immediately to Assign Safety Desk via:

Fax: +43 (0) 512 281514 77 or e-mail: SafetyDesk@assigndmb.com

(24h Safety Hotline: +43 (0) 676 844033835)

All dates should be provided as DD/MMM/YYYY.

1. PROTOCOL INFORMATION:		
Protocol Short Title:	VLN Cigarette Consumption Study	IND no.: N/A
Celerion Protocol no.:	CA24914	Country: USA
2. REPORTER'S DETAILS:		
Reporter's name:	(b) (6)	
Address:	621 Rose St. Lincoln, NE 68502	
Site:	Celerion	
Email:	(b) (6) @ celerion.com	
Phone/Fax:	(b) (6)	
3. REPORT INFORMATION: (please use the same form for initial and follow-up report, if possible)		
Initial Report:	Date: 17 5 2018	(b) (6)
	dd mmm yyyy	Reporter's name and Signature
Follow-Up No _____:	Date: 20	Reporter's name and Signature
	dd mmm yyyy	Reporter's name and Signature
Follow-Up No _____:	Date: 20	Reporter's name and Signature
	dd mmm yyyy	Reporter's name and Signature
Follow-Up No _____:	Date: 20	Reporter's name and Signature
	dd mmm yyyy	Reporter's name and Signature
4. SUBJECT INFORMATION:		
Date of birth:	Race:	Height:
(b) (6)	<input checked="" type="checkbox"/> White/Caucasian	1,6,1 cm
	<input type="checkbox"/> Black/African American	
	<input type="checkbox"/> Asian	
	<input type="checkbox"/> Native Hawaiian/other Pacific Islander	
	<input type="checkbox"/> American Indian/Alaska Native	
	<input type="checkbox"/> Other:	
Gender:		Weight:
<input checked="" type="checkbox"/> female		6,2,6 kg
<input type="checkbox"/> male		

VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001023

Report Form

5. SERIOUS ADVERSE EVENT: (short term; please provide ONE diagnosis, if possible)

Subarachnoid hemorrhage

6. SERIOUS ADVERSE EVENT INFORMATION:

Awareness date: 17 | 7 | 2018 | 8 | Date the investigator became aware of the event
dd mmm yyyy

Onset date of event: (b) (6) | Date the event started, i.e. the first symptoms occurred
dd mmm yyyy

Stop date of event: | | | 20 | | | Date, when the event (including symptoms) subsided, stabilized with sequelae, or date of subject's death
dd mmm yyyy

7. SEVERITY OF SAE:

Mild Moderate Severe

8. SERIOUSNESS CRITERIA: (please tick all that apply) yes no (non-serious event of special interest)

- Inpatient hospitalization or prolongation of existing hospitalization* Persistent or significant disability/incapacity or substantial interruption to conduct normal life functions
- Congenital anomaly/birth defect Life-threatening
- Important medical event Death**
(Please specify in the SAE description field on page 3 and only tick this criterion if no other applies)

* if hospitalization: Date of admission: (b) (6) | Date of discharge: | | | 20 | | |
dd mmm yyyy dd mmm yyyy

** if death: Date of death: | | | 20 | | |
dd mmm yyyy

Probable cause of death: _____ Autopsy performed? yes no
(if yes, please provide summary of autopsy report in the SAE description on page 3)

9. SAE OUTCOME: (please tick only one)

- resolved worse
- improved fatal
- unchanged unknown/lost to follow-up

VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

001023

Report Form

10. STUDY PRODUCT INFORMATION:						
Study product name	First use			Last use prior to SAE		
	dd	mmm	yyyy	dd	mmm	yyyy
<input type="checkbox"/> Subject's usual brand non-mentholated filtered king size cigarettes			20			20
<input type="checkbox"/> Subject's usual brand mentholated filtered king size cigarettes			20			20
<input checked="" type="checkbox"/> Non-mentholated VLN cigarettes	02	AUG	20 18	14	SEP	20 18
<input type="checkbox"/> Mentholated VLN cigarettes			20			20

11. ASSESSMENT OF CAUSALITY:

likely probably possibly unlikely unrelated

12. ACTION TAKEN WITH STUDY PRODUCT: (please tick only one)

Unchanged Interrupted Reduced Withdrawn

13. ACTION TAKEN TO TREAT SAE:

none
 drug therapy started
 diagnostic test performed
 non-drug therapy started
 unknown

other (please specify):

14. SERIOUS ADVERSE EVENT DESCRIPTION:

Describe event fully. Include baseline medical status (medical history, signs and symptoms, diagnosis, diagnostic test results, clinical course, treatment (all drugs/procedures used as interventions for SAE), outcome, hospital course for hospitalizations, etc. Please do not attach test results and hospital records but provide a short summary of relevant findings. Please also provide rationale for relationship assessment.

On (b) (6) subject 001023 was admitted to the hospital. According to her son, it was for a subarachnoid hemorrhage. The son stated that she underwent medical procedures to drain the blood in her brain. The physician said that there's at least a 10 day recovery time. Celerion was notified of this SAE on 17SEP2018

VLN Cigarette Consumption Study

Confidential

Sponsor:

Subject ID

SAE

22nd Century Group, Inc.

□ □ □ □ □ □

Report Form

Empty lined area for text entry.

15. INVESTIGATOR'S SIGNATURE:

Investigator's name: PHILIP MATHEW

Investigator's signature: **(b) (6)**

Date: 17 SEP 2018
dd mmm yyyy

FOR DRUG SAFETY DEPARTMENT ONLY - NOT TO BE FILLED IN BY REPORTER:

Received date: 18-Sep-2018

Time: 01:52

Tracked:

Case Number: VLN-C-Study-001-023-01

Signature: **(b) (6)**